AzTrials
AzTrials

NormotensiveNCT03948373

Normotensive OSA Patients With Dipper Circadian Blood Pressure Pattern

A study testing CPAP treatment in people with Normotensive and Sleep Apnea, Obstructive, run by Sociedad Española de Neumología y Cirugía Torácica at 1 site in Spain.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The principal objective is to evaluate the effect of CPAP treatment on blood pressure (BP) in normotensive patients with dipper circadian pattern with sleep apnea-hypopnea syndrome (SAHS). Read more about this study

Who is it for?
Ages 18 to 100 years
Conditions the study is for
Normotensive, Sleep Apnea, Obstructive
What is being tested?
CPAP treatment
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
64 participants
Where
1 siteSpain
Study dates
7 May 2019to Dec 2025
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 100 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Men and women over 18 years of age
  • Referred to the sleep unit for suspected OSA
  • Being normotensive and presenting an AHI ≥ 30 in the sleep study
  • Signature of the informed consent.

Who cannot join

  • Previous CPAP treatment
  • Significant somnolence defined by an Epworth Sleepiness Scale (ESS) score higher than 18
  • Psychophysical inability to complete questionnaires
  • Previous diagnosis or suspicion of another sleep disorder
  • Presence of more than 50% of central apneas or Cheyne-Stokes respiration
  • Having a serious chronic disease: neoplasia, renal failure, severe chronic obstructive pulmonary disease, chronic depression and other chronic limiting diseases
  • Medical history that may interfere with the objectives of the study or, in the opinion of the researcher, may compromise the conclusions
  • Any medical, social or geographical factor that may endanger the patient's compliance 9-Having a profession of high risk (professional driver).

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Spain1 site, 1 recruiting
  • Hospital Arnau de Vilanova-Santa Maria

    Lleida, 25198

    Ferran Barbe, MD

    Recruiting

Other trials in Spain

About this study

Official title: CPAP Effect in Nocturnal Blood Pressure in Normotensive Patients With Dipper Circadian Pattern and Severe Obstructive Sleep Apnea (OSA)

The principal objective is to evaluate the effect of CPAP treatment on blood pressure (BP) in normotensive patients with dipper circadian pattern with sleep apnea-hypopnea syndrome (SAHS). The secondary objectives are: i) To evaluate the prevalence of the different circadian patterns of BP in ambulatory blood pressure monitoring (ABPM) ii) To establish the relationship between CPAP compliance and BP response; iii) Identify which ABPM variables and biomarkers are related to BP response; iv) Evaluate changes in the biomarkers' profile with the CPAP treatment. Methodology: Open-label, parallel, prospective, randomized and controlled trial including normotensive patients diagnosed with severe SAHS without significant somnolence. 64 patients with dipper circadian pattern will be included and will be randomized to receive CPAP (32) or conservative treatment (32). ABPM and blood sample collection will be performed at the beginning of the study and at 3 months.

Read the detailed description
  1. Recruitment: Normotensive subjects referred to the sleep unit of the Hospital Santa Maria (Spain) who are diagnosed of severe OSA (AHI≥30) by a sleep study and dipper circadian blood pattern confirmed by ABPM and who do not present significant somnolence (Epworth≤18) will be included in the study.
  2. Definition of the groups: Patients will be randomized to receive one of the following treatments:
  3. CPAP: Patients who will receive CPAP treatment. The CPAP titration will be carried out with an automatic or manual CPAP according to usual clinical practice.
  4. Conservative treatment: Patients who will receive conservative treatment based on hygienic-dietetic measures.
  5. Randomization: It will be carried out with an automated platform
  6. Duration of the treatment: All patients randomized to CPAP will begin treatment as soon as possible after randomization, and will continue treatment until the study ends (3 months). Patients who interrupt treatment will be excluded from the study. ABPM and blood sample collection will be performed on all included patients at the beginning of the study and at 3 months under treatment (CPAP or conservative care).
  7. Follow-up: All patients will be evaluated at the beginning of the study (T0), at first month (T1) and at three months (T2), during the follow-up period.
Being tested
CPAP treatment
Medical subject headings
Sleep Apnea, Obstructive

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CPAP treatmentDevice

    In this group of patients (CPAP group) will be prescribed CPAP treatment at an optimal pressure. It will be performed a CPAP titration with an automatic or manual CPAP according to usual clinical practice.

Study groups in NCT03948373
Study groupRoleWhat they receive
CPAP treatmentExperimentalGroup of patients who will receive CPAP treatment
Receives: Device: CPAP treatment
Conservative measuresNo interventionPatients who will receive conservative treatment based on hygienic-dietetic measures

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Effect of CPAP treatment on BP according to the circadian BP pattern in normotensive dipper patients with severe OSA

    Change in mmHg in the blood pressure of the ambulatory blood pressure monitoring parameters after the treatment

    Measured: 3 years

Secondary outcomes (4)
  1. Prevalence of the different circadian BP patterns (dipper/no-dipper) in the ABPM of normotensive subjects diagnosed with severe OSA without significant somnolence (Epworth≤18)

    The prevalence of each circadian patterns will be calculated from the baseline ambulatory blood pressure monitoring data

    Measured: 3 years

  2. Relationship between compliance with CPAP treatment and the blood pressure change in these patients

    The relation between CPAP compliance (mean hours per night) and change in mean nighttime BP using multivariate models in patients randomized to CPAP treatment.

    Measured: 3 years

  3. Ambulatory blood pressure parameters different to circadian blood pressure that are related to the response to CPAP treatment

    Using all the ABPM variables we will proceed to the identification of variables that are related to the change in mean nocturnal BP in patients treated with CPAP.

    Measured: 3 years

  4. Changes in the biomarkers' profile after CPAP treatment

    Using the the blood samples obtained in the baseline and 3 months visit it will be evaluated possible changes in the biomarkers profile after CPAP treatment.

    Learning Phase: complete profile analysis (754 miRNAs) will be carried out in 24 patients Learning Phase: complete profile analysis (754 miRNAs) will be carried out in 24 patients representative of the change in BP in treated patients. The miRNAs associated with the change in BP will be identified from the 754 miRNAs potentially present in serum and plasma.

    Validation Phase: Specific primers will be designed for the real-time PCR amplification of the genes for which we have found a significant association The miRNAs found will be analyzed after 3 months of treatment. Analysis of biomarkers. Immunoassay techniques will evaluate the following markers before and after treatment: angiotensin I, II and III, plasma renin activity, atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and endogenous ouabain.

    Measured: 3 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 May 2019
  2. Study start7 May 2019
  3. Primary completionDec 2025 (estimated)
  4. Study completionDec 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
This is an open-label, parallel, prospective, randomized and controlled trial.
Masking
Single blind
Who is masked
Investigator
Enrolment
64 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03948373
Sponsor's protocol ID
Dipper-OSA
Status last verified
Feb 2025
First submitted
6 May 2019
Last updated
26 Feb 2025
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing CPAP treatment in people with Normotensive and Sleep Apnea, Obstructive, run by Sociedad Española de Neumología y Cirugía Torácica at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 26 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Ferran Barbé Illa, MD (+34 (973) 70 53 72, febarbe.lleida.ics@gencat.cat), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Effect of CPAP treatment on BP according to the circadian BP pattern in normotensive dipper patients with severe OSA (time frame: 3 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Feb 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in